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Abstract
Influenza virus infection increases susceptibility to bacterial infection and mortality, which
the antiviral drug, Tamiflu, is reported to have the possible benefit of reducing both[1] . It
was hypothesized that Tamiflu induces gut microbiome composition changes in Tamiflu- or
PBS-treated mice after Influenza A Virus (IAV) and Methicillin-resistant Staphylococcus
aureus (MRSA) coinfection. After IAV-MRSA coinfection, feces were collected from
Tamiflu or PBS-treated mice. In this project, the bacterial DNA was extracted from the feces
and was analyzed by qPCR using phylum and genus specific primers to examine changes in
the gut microbiota. The phylum Firmicutes showed the treatment group increased in relative
abundance by 7% and the control decreased by 7%. The phylum Bacteroidetes showed the
treatment group’s relative abundance showed no change and the control increased by 25%.
When looking at the phylum, Tenericutes and TM7, there was a spike in relative abundance
expression the days immediately following MRSA infection in the control, but not the
Tamiflu treatment group. These results suggest the administration of Tamiflu in mice
coinfected with IAV and MRSA leads to different gut microbiome composition changes
when compared with mice that did not receive the Tamiflu treatment.
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Fig. 1: Amplification curve from Roche Light Cycler 480 (only 10 primer sets shown for ease of
visualization, which demonstrate the primers were run in triplicate. Colors correspond to triplicated samples
from one DNA sample.)

Introduction
In the 2018-2019 Flu season, one in every thousand people who got the flu died from it [2].
When a host is infected with IAV, there are dynamic changes in the gut microbiome [3].
The drug Tamiflu is prescribed to lessen the severity of IAV symptoms, but also has the
possible benefit of reducing mortality caused by coinfection [1]. Little research has been
done on how Tamiflu impacts the composition of the gut microbiome. It was hypothesized
that Tamiflu induces gut microbiome composition changes in Tamiflu or PBS treated mice
after IAV/ MRSA coinfection. Mouse feces were collected from two groups of mice
coinfected with IAV (on day 0) and MRSA (on day 4) and administered Tamiflu or PBS
(on days 4-8). In this project, the bacterial DNA was extracted from mouse feces using the
QIAamp Fast DNA Stool Mini Kit. To detect the gut microbiota compositional changes, 2
primers selected for all bacteria, 22 primers that selected for the DNA of the 8 most
prominent gut bacterial phyla and 3 genera known to play an important role in host
immunity were used. The bacterial composition and relative abundance were determined
from the analysis of mouse fecal samples using quantitative PCR.

Methods

(Day 0- before IAV infection, at the phylum level)
Fig 2: Graph of Bacterial DNA’s Crossing points based on crossing points from Amplification analysis
Firmicutes and Bacteroidetes are more abundant.
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Bacteria Expression Ratios in each Phylum
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The phylum Firmicutes showed the treatment group increased in relative abundance by 7% and
the control decreased by 7%. The phylum Bacteroidetes showed the treatment group decreased
in relative abundance by 1% and the control increased by 25%. When looking at the bacteria
phyla Tenericutes and TM7, there was a spike in relative abundance expression the days
immediately following MRSA infection in the control, but not the Tamiflu treatment group.
These results show there are noticeable differences in the population composition, and
expression ratios of the mice that were administered the Tamiflu treatment compared to the
control. Going forward, Mass Spectrometry will be used to study the proteomics of mouse feces
to determine if there are observable chemical changes occurring in tandem with shifts in
bacterial composition or expression. Further research has the potential of leading to the creation
of a complimentary probiotic that can speed up recovery, protect the host from severity of
secondary infections and decrease the number of hospitalizations and deaths related to the
Influenza virus.
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Fig. 4: The two graphs above show the specific expression ratios specific bacteria, Tenericutes
and TM7 (2 of 11 bacteria phylum that were tested) over the course of 18 days. Treatment
groups depicted are the mice that were infected with IAV, MRSA and were either given the
Tamiflu treatment or PBS (days 4-8). The above graphs show a spike in expression the days
immediately following MRSA infection in the control, but not the Tamiflu treatment group.
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